Learning from the COVID-19 Pandemic and AKI Evolution for Extracorporeal and Adsorption Techniques in Kidney Replacement Therapy
COVID
; 2(9):1214-1227, 2022.
Article
in English
| MDPI | ID: covidwho-2005953
ABSTRACT
Increased mortality has been observed in patients who develop acute kidney injury (AKI) in the setting of coronavirus disease 2019 (COVID-19), which has led to the approval of extracorporeal kidney support by the FDA. We analyzed the existing literature to compare the efficacy and therapeutic benefits of various extracorporeal modalities for the oXiris membranes and CytoSorb cartridge in high-flow continuous kidney replacement therapy (HFCKRT). AKI due to COVID-19 is mediated by a state of systemic inflammation (cytokine storm syndrome), leading to multiple organ dysfunction. Although there is no consensus on a protocol for providing kidney support therapy, clinically oriented studies have shown the capacities of oXiris and CytoSorb filters to effectively filter out pro-inflammatory components, leading to improved clinical outcomes in critically ill patients. In this review, we study the development of cytokine storm syndrome, important clinical evidence regarding the roles of various adsorption techniques in kidney support therapy in this setting, and a protocol influenced by FDA recommendations for oXiris and CytoSorb membranes.
Full text:
Available
Collection:
Databases of international organizations
Database:
MDPI
Language:
English
Journal:
COVID
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS